flecainide has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 1 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Sabi, A | 1 |
| Daly, D | 1 |
| Hoefer, P | 1 |
| Kinsella, GK | 1 |
| Metais, C | 1 |
| Pickering, M | 1 |
| Herron, C | 1 |
| Kaza, SK | 1 |
| Nolan, K | 1 |
| Dolly, JO | 1 |
1 other study available for flecainide and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction.
Topics: Animals; Cell Line; Corpus Callosum; Demyelinating Diseases; Drug Design; Humans; Kv1.1 Potassium Ch | 2017 |